Development of biomedical products: vaccines, antibodies, gene therapy drugs, etc.
Platform for developing corpuscular adjuvant-based recombinant protein vaccines. The use of an adjuvant for betulin-based vaccines makes it possible to increase immunogenicity (efficacy, protectiveness), the speed of development and duration of the immune response, optimize the antigen dose, and prevent competition of antigens in combination vaccines.
Primary/booster vaccination SARS-COV-2
Russia’s first subunit recombinant vaccine based on spherical particles with the surface protein of coronavirus.
The antigen used is part of the RBD domain of the S protein of coronavirus SARS-CoV-2. It is the RBD domain in response to which the immune system produces the largest number of virus-neutralizing antibodies.
The Betuvax-CoV-2 vaccine does not contain inactivated or weakened particles of the new SARS-COV-2 coronavirus, does not contain vector viruses (adenovirus, influenza, measles, etc.), does not contain genetic material (RNA or DNA), inorganic adjuvants, so it is designed as a tool for multiple revaccinations, since it potentially does not have any short-term adverse reactions and does not cause excessive antigenic load.
The Betuvax-CoV-2 vaccine is designed so that it can be quickly optimized for new strains of coronavirus.
Influenza vaccination
Quadrivalent subunit influenza vaccine consisting of surface antigens of the influenza virus adsorbed on the adjuvant surface. The drug does not contain preservatives or stabilizing agents that could cause post-vaccination complications.
The vaccine showed a high safety profile and low reactogenicity in preclinical and clinical trials due to its low antigen content (one vaccine dose contains 5 μg of hemagglutinin from each of the four seasonal vaccine strains).
Influenza + COVID-19 Combi vaccine
Combined recombinant vaccine for protection against four seasonal strains of influenza viruses, as well as a component protecting against the SARS-CoV-2 virus.
The vaccine was developed on the basis of the TetraFluBet and Betuvax-CoV-2 vaccines.
Immunomodulator
The company began developing a substance with immunobiological activity. Preclinical studies are currently being completed.
HPV vaccination
Allergies
Recombinant plasmid DNA-based gene therapy drugs stimulate the formation and growth of collateral vessels. Indications: treatment of conditions that require the development of collateral circulation.
Lower Limb Ischemia
The action of the drug is fundamentally different from all known drugs for the treatment of chronic lower limb ischemia (CLI). This is the world’s first gene therapy drug based on the “therapeutic angiogenesis” mechanism (therapeutic vessel growth).
Neovasculgen stimulates the production of vascular endothelial growth factor VEGF-165, resulting in the growth of new microvasculature at the site of drug administration, which results in better blood supply to the ischemic area.
Clinically, patients show a more than 5-fold increase in pain-free walking distance (PFWD) and an improvement of such indicators as tissue oxygenation, ankle-brachial index, linear blood flow velocity.
The drug is included in the “List of Vital and Essential Drugs” and “National and Clinical Guidelines for CLI Treatment.”
Diabetic Foot Syndrome
Interstitial Cystitis
Androgenetic Alopecia
Peripheral Nerve Injuries
Development of gene therapy drugs for the treatment of rare neuromuscular diseases.
Dysferlinopathy (AAV)
Development of original next-generation biopharmaceuticals based on shark nanobody inhibitors, including drugs for cardiovascular diseases and cancer.
CVD, oncology
The biopharmaceutical drug binds to PD-L1 to activate the immune system to fight tumor cells.